moderate - Interventional procedures are semi-discretionary with 60-70% driven by urgent/emergent cases (STEMI, stroke, cancer) that are recession-resistant, but 30-40% are elective procedures (stable angina, peripheral claudication) that can be deferred during economic stress. Hospital capital budgets and staffing levels also affect procedure scheduling capacity. GDP growth correlates with elective procedure volumes and hospital purchasing patterns, but the relationship is dampened by aging demographics (Medicare-driven demand) and clinical guideline expansion favoring minimally invasive techniques.

Rising rates have modest negative impact through two channels: (1) higher borrowing costs on $250M+ debt balance (mix of fixed/variable), though Debt/Equity of 0.57 is manageable, and (2) valuation multiple compression as med-tech stocks typically trade on forward P/E and rising discount rates reduce present value of future earnings. Demand side is largely insulated as procedures are reimbursed by Medicare/commercial insurance, not consumer-financed. Hospital system capital spending can be constrained by higher financing costs, but Merit's consumables model is less affected than capital equipment vendors.

value - Stock trades at 2.8x P/S and 14.4x EV/EBITDA, below historical medtech averages, attracting value investors betting on margin expansion and multiple re-rating. Recent 27% one-year decline creates contrarian opportunity if procedural volumes stabilize and operational execution improves. 5% FCF yield provides downside support. Growth investors are less attracted given single-digit EPS growth, but improving organic growth and M&A could shift sentiment.